AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer

Journal of International Medical Research

Volumn 39, Issue 1, 2011, Pages 78-85

  Kang, M W ^a,b,c   Lee, E S ^a,b   Yoon, S Y ^a   Jo, J ^a   Lee, J ^a   Kim, H K ^a   Choi, Y S ^b   Kim, K ^b   Shim, Y M ^b   Kim, J ^a,b   Kim, Hojoong ^b  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Chungnam National University College of Medicine   (South Korea)

Author keywords

AKR1B10; Biomarker; Lung cancer; mRNA; Smoking

Indexed keywords

ALDO KETO REDUCTASE FAMILY MEMBER B10 PROTEIN; MESSENGER RNA; TUMOR PROMOTER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CELL DIFFERENTIATION; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; TUMOR CLASSIFICATION; TUMOR VOLUME; VALIDATION STUDY;

EID: 79952970580     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900110     Document Type: Article

References (24)

1. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37(suppl 8): S4-S66.
2. Wingo PA, Ries LA, Giovino GA, et al: Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 1999; 91: 675-690.
3. Carney DN: Lung cancer-time to move on from chemotherapy. N Engl J Med 2000; 346: 126-128.
4. Kim B, Lee HJ, Choi HY, et al: Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res 2007; 67: 7431-7438.
5. Cao D, Fan ST, Chung SS: Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem 1998; 273: 11429-11435.
6. Scuric Z, Stain SC, Anderson WF, et al: New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology 1998; 27: 943-950.
7. Fukumoto S, Yamauchi N, Moriguchi H, et al: Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res 2005; 11: 1776-1785.
8. Yoshitake H, Takahashi M, Ishikawa H, et al: Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer. Int J Gynecol Cancer 2007; 17: 1300-1306.
9. Ma J, Yan R, Zu X, et al: Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-a in breast cancer cells. J Biol Chem 2008; 283: 3418-3423.
10. Nagaraj NS, Beckers S, Mensah JK, et al: Cigarette smoke condensate induces cytochromes P450 and aldo-keto reductases in oral cancer cells. Toxicol Lett 2006; 165: 182-194.
11. Li CP, Goto A, Watanabe A, et al: AKR1B10 in usual interstitial pneumonia: expression in squamous metaplasia in association with smoking and lung cancer. Pathol Res Pract 2008; 204: 295-304.
12. Hsu NY, Ho HC, Chow KC, et al: Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res 2001; 61: 2727-2731.
13. Gallego O, Belyaeva OV, Porte S, et al: Comparative functional analysis of human medium-chain dehydrogenases, short-chain dehydrogenases/reductases and aldo-keto reductases with retinoids. Biochem J 2006; 399: 101-109.
14. Spite M, Baba SP, Ahmed Y, et al: Substrate specificity and catalytic efficiency of aldo-keto reductases with phospholipid aldehydes. Biochem J 2007; 405: 95-105.
15. Blaner WS, Olson JA: Retinol and retinoic acid metabolism. In: The Retinoid: Biology, Chemistry, and Medicine, 2nd edn (Sporn MB, Roberts AB, Goodman DS, eds). New York: Raven Press, 1999; pp 229-255.
16. Crosas B, Hyndman DJ, Gallego O, et al: Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem J 2003; 373: 973-979.
17. Vander Jagt DL, Hunsaker LA, Robinson B, et al: Aldehyde and aldose reductases from human placenta. Heterogeneous expression of multiple enzyme forms. J Biol Chem 1990; 265: 10912-10918.
18. Martin HJ, Breyer-Pfaff U, Wsol V, et al: Purification and characterization of AKR1B10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab Dispos 2006; 34: 464-470.
19. Zeindl-Eberhart E, Klugbauer S, Dimitrijevic N, et al: Proteome analysis of rat hepatomas: carcinogen-dependent tumor-associated protein variants. Electrophoresis 2001; 22: 3009-3018.
20. Zeindl-Eberhart E, Haraida S, Liebmann S, et al: Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. Hepatology 2004; 39: 540-549.
21. Penning TM: AKR1B10: a new diagnostic marker of non-small cell lung carcinoma in smokers. Clin Cancer Res 2005; 11: 1687-1690.
22. Woenckhaus M, Klein-Hitpass L, Grepmeier U, et al: Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers. J Pathol 2006; 210: 192 -204.
23. Yan R, Zu X, Ma J, et al: Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention. Int J Cancer 2007; 121: 2301-2306.
24. Gallego O, Ruiz FX, Ardèvol A, et al: Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci USA 2007; 104: 20764-20769.